Fortis Healthcare Limited
Fortis Healthcare Limited operates in Hospital, part of the Healthcare sector. It booked ₹2,545 cr of revenue in its latest quarter (Q1 FY27) and kept 10.5% of sales as profit. It is the 4th largest of 9 Hospital companies we track, by market value.
| Segment | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | Share |
|---|---|---|---|---|---|---|---|
| Healthcare | 3,124 | 4,264 | 5,107 | 5,686 | 6,528 | 7,773 | 75% → 84% |
| Diagnostic | 589 | 791 | 683 | 699 | 1,407 | — | — |
| Diagnostics | 446 | 814 | 665 | 673 | — | 1,527 | 11% → 16% |
| Total | 4,158 | 5,869 | 6,455 | 7,058 | 7,935 | 9,299 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“The Company is engaged in the business of providing healthcare services and deals with patients which are its primary customers. 3.”
“The Company is primarily engaged of the defined benefit in the business of healthcare services.”
“is to become a digital-first to requirements”, Patient Safety practices lead to company, driving efficiency and excellence across “prevention of harm”.”
Healthier than 52% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 40
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in FORTIS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 5%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹2,545 cr |
| Other Income | ₹14 cr |
| Total Income | ₹2,560 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹586 cr |
| Inventory Change (±) | ₹-13 cr |
| Employee Benefit Expense | ₹404 cr |
| Finance Costs | ₹80 cr |
| Depreciation & Amortisation | ₹122 cr |
| Other Expenses | ₹1,031 cr |
| Total Expenses | ₹2,210 cr |
| Exceptional Items | ₹10 cr |
| Profit before Tax | ₹359 cr |
| Tax Expense | ₹90 cr |
| Share of JV / Associates | ₹4 cr |
| Net Profit | ₹273 cr |
| Net margin on total income | 10.7% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 2,265 cr | 2,365 cr | 2,545 cr |
| Total income | 2,273 cr | 2,369 cr | 2,560 cr |
| Expenses | 1,965 cr | 2,039 cr | 2,210 cr |
| Profit before tax | 262 cr | 318 cr | 359 cr |
| Tax | 68 cr | 53 cr | 90 cr |
| Net profit (owners' share) | 194 cr | 266 cr | 266 cr |
| Net margin (owners' share, on revenue) | 8.6% | 11.2% | 10.5% |
| EPS (₹) | 2.57 | 3.52 | 3.53 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹8,769 | ₹1.26 L cr | 54.3 | 24.5% | 8.2% | — |
| Max Healthcare Institute Limited | ₹1,037 | ₹1.01 L cr | 78.1 | 12.0% | 13.6% | — |
| Manipal Health Enterprises Limited | ₹722 | ₹85,125 cr | 92.0 | — | 7.5% | — |
| Fortis Healthcare Limitedthis company | ₹886 | ₹66,897 cr | 62.8 | 10.8% | 10.5% | — |
| Aster DM Quality Care Limited | ₹761 | ₹39,412 cr | 613.4 | 1.4% | 1.2% | — |
| Global Health Limited | ₹1,424 | ₹38,273 cr | 60.2 | 16.0% | 12.2% | — |
| Narayana Hrudayalaya Ltd. | ₹1,869 | ₹38,187 cr | 45.8 | 18.3% | 7.7% | — |
| Krishna Institute of Medical Sciences Limited | ₹792 | ₹33,258 cr | 190.3 | 7.4% | 3.5% | — |
| Dr. Agarwal's Health Care Limited | ₹500 | ₹15,855 cr | 87.4 | 8.9% | 7.4% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1 / share | 24 Jul 2026 |
| Dividend | ₹1 / share | 25 Jul 2025 |
| Dividend | ₹1 / share | 24 Jul 2024 |
| Dividend | ₹1 / share | 20 Jul 2023 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.